Metsil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metsil

Property Description
Active ingredient Metoclopramide
Form Tablets, Oral solution, Injection solution
Pharmacological class Prokinetic agent, Antiemetic
General purpose Management of nausea, vomiting, and impaired stomach emptying
Origin Synthetic compound (Benzamide derivative)

What Type of Medicine is Metsil (Metoclopramide)?

Metsil is a prescription-only pharmaceutical preparation whose sole active ingredient is the substance Metoclopramide (as the hydrochloride salt). This medication is chemically identified as a benzamide derivative and is formally classified as a prokinetic agent and a primary antiemetic. The compound is utilized for managing acute gastrointestinal issues and is used in the management of fundamental gastrointestinal symptoms.

Composition and Available Forms of Metsil

The composition of Metsil is strictly single-ingredient, containing Metoclopramide alongside necessary excipients to ensure stability and proper delivery. The drug is produced in several distinct pharmaceutical preparations to accommodate varying clinical needs, including standard tablets for oral use, an oral solution with a measured dose, and a sterile injection solution packaged in ampoules. This flexibility permits delivery via the oral, intravenous (IV), and intramuscular (IM) routes. The injectable form has a rapid absorption profile, making it suitable for situations requiring immediate therapeutic action, such as controlling severe episodes of vomiting.

What is the General Purpose of Metsil?

The general purpose of Metsil is to manage and mitigate symptoms stemming from various gastrointestinal motility disorders and to suppress the sensations of nausea and the physical act of vomiting. It achieves this by promoting the forward movement of contents from the stomach while simultaneously interrupting the nerve signals for sickness in the brain's specialized trigger zone. Metoclopramide is used in treating both acute and chemotherapy-induced nausea and vomiting. The medicine is used to control severe episodes of sickness, serving as an option in acute care settings.

Regulatory References

  1. WHO Essential Medicines List
  2. EMA Metoclopramide Referral

What side effects are possible with Metsil?

Possible side effects and safety information

The official safety profile of Metoclopramide is defined by several regulatory classifications detailing potential adverse reactions and safety constraints. The risks are formally grouped by frequency and the body system affected, providing a structured overview of the medicine’s safety characteristics as documented in governmental sources like the FDA and EMA.

Key Adverse Reactions and Safety Categories

Category Description
Movement Disorders The primary safety concern, encompassing Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia (TD).
Duration Constraint Official regulatory limit restricting use to generally 12 weeks or less to minimize the risk of developing TD.
Cardiovascular Risks Includes serious events such as cardiac arrest and severe bradycardia, particularly noted with rapid intravenous administration.
Neuropsychiatric Risks Adverse reactions classified in this domain include drowsiness, depression, and the serious, rare risk of Neuroleptic Malignant Syndrome (NMS).

Frequency and System-Organ Effects

Adverse reactions classified as Common in regulatory documents often include drowsiness, diarrhea, fatigue, and forms of restlessness or akathisia. Less common effects include hormonal changes linked to hyperprolactinemia (such as galactorrhea or amenorrhea). The regulatory framework highlights that the risk of Acute Extrapyramidal Symptoms is generally highest at the beginning of treatment or even after a single administration.

Population-Specific Safety Notes

The official labeling notes specific safety considerations for certain patient groups. Older adults face an increased risk for developing Tardive Dyskinesia with prolonged exposure. Furthermore, the label advises that pediatric patients have a higher incidence of acute Extrapyramidal Symptoms, and the medicine is contraindicated in children under one year of age due to neurological and other safety concerns.

Overdose and Emergency Response

Overdose Scope and Documented Manifestations

Official regulatory documents indicate that overdose presentations frequently involve neurological and gastrointestinal systems. Documented manifestations include Extrapyramidal Reactions (EPRs), somnolence, lethargy, disorientation, seizures, and diarrhea. The most severe outcomes recognized by regulators include the life-threatening neurological syndrome Neuroleptic Malignant Syndrome (NMS). For the injectable form, circulatory collapse, severe bradycardia, and cardiac arrest are documented risks. Special consideration is noted for premature and full-term neonates due to the specific risk of Methemoglobinemia following high exposure.

Required Emergency Actions and Management

Regulatory authorities strictly mandate that patients exhibiting symptoms such as EPRs, NMS, or Tardive Dyskinesia (TD) must seek immediate medical attention, and the medication must be discontinued immediately. Treatment is uniformly described as symptomatic and supportive. The regulatory profile notes that while general overdose symptoms are often self-limiting, typically resolving within 24 hours, specific interventions are required for complications. For instance, Methylene blue is documented as the reversal agent for Methemoglobinemia, and although no specific antidote exists for systemic intoxication, benzodiazepines or anticholinergic drugs may be used to manage neurological symptoms. Dialysis is noted as not likely to be an effective method of drug removal.

Therapeutic Uses of Metsil

Quick Facts

  • Relieves symptoms associated with excess gas in the digestive tract.
  • Provides management for uncomfortable feelings of fullness, pressure, and bloating.
  • May be used for conditions like functional dyspepsia and aerophagy where trapped gas is a factor.

Metsil is a medication used to provide relief from symptoms associated with excess gas in the gastrointestinal (GI) tract. Its therapeutic purpose is primarily focused on the management of discomfort caused by trapped air.

This medication is indicated for the temporary alleviation of conditions characterized by the presence of unwanted gas, which may include uncomfortable feelings of pressure, fullness, or bloating. It is frequently employed as an adjunct in the symptomatic management of various digestive issues, such as functional dyspepsia, where excess gas may contribute to discomfort, and aerophagy (the swallowing of air).

Metsil may also be utilized to support the preparation of patients undergoing certain diagnostic procedures, such as radiological examinations of abdominal structures, by facilitating the dispersion of gas pockets that could obscure visibility. The active ingredient, simethicone, acts to reduce the surface tension of gas bubbles in the gut.

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Metsil

Populations for Whom Use is Contraindicated

Metsil is strictly prohibited in patients with conditions that pose a risk when gastrointestinal motility is increased, including gastrointestinal hemorrhage, mechanical obstruction, or perforation. Use is also contraindicated in individuals with pheochromocytoma (a tumor of the adrenal gland), a history of tardive dyskinesia, or severe neurological conditions like epilepsy.

Age and Organ Function Restrictions

  • Children: Use is absolutely contraindicated in children less than 1 year of age. For those aged 1 to 18 years, use is severely restricted to specific, second-line treatment indications.
  • Adults: Approved use is subject to mandatory duration limits, which vary by region (e.g., maximum 5 days in the European Union, or maximum 12 weeks in the US).
  • Older Adults: A dose reduction should be considered in elderly patients, particularly due to increased risk of neurological side effects and potential decline in organ function.
  • Organ Impairment: Patients with severe renal impairment or severe hepatic impairment require an official reduction in the prescribed dose due to compromised drug clearance.

Pregnancy and Lactation Status

The medicine is generally not recommended for breastfeeding women, and use should be avoided at the end of pregnancy due to the officially documented potential for extrapyramidal symptoms in the newborn.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metoclopramide (Metsil) has documented interactions spanning pharmacokinetic, pharmacodynamic, and antagonism classifications, as defined by regulatory authorities.

Regulatory Restrictions and Prohibited Combinations

Co-administration with Dopaminergic Agonists, such as Levodopa, is formally contraindicated because the medication acts as a dopamine antagonist, neutralizing the therapeutic effect of the agonist. The use of Metoclopramide is also strictly prohibited alongside other drugs that are likely to cause extrapyramidal reactions, due to an additive risk documented in official labeling. Combination with Monoamine Oxidase Inhibitors (MAOIs) is advised against due to a reported increased risk of hypertension.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Metoclopramide is metabolized primarily by the CYP2D6 enzyme. Strong CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine) officially increase Metoclopramide's systemic exposure (plasma concentration). This is a significant interaction requiring cautious use. Conversely, Metoclopramide modifies the absorption of other medicines; it decreases the bioavailability of Digoxin and accelerates the absorption of Paracetamol and Aspirin due to its prokinetic effect. Central Nervous System (CNS) Depressants, including alcohol and opioid analgesics, may produce an additive sedative effect, leading to reinforced drowsiness. The official profile notes that in cases of Renal Impairment or CYP2D6 Poor Metabolizer status, the clearance of Metoclopramide is reduced, increasing the risk of drug accumulation.

Mechanism of Action

The drug Metsil (Simethicone) operates exclusively through a physical mechanism localized within the gastrointestinal lumen; it is not absorbed systemically. Its action is centered on the gas-liquid interface, where it modifies the properties of the fluid within the gut.

Modulating Surface Tension

Metsil functions as an inert surfactant that targets the small, tenacious gas bubbles entrapped within the mucus lining and chyme. It reduces the surface tension of these minute, highly dispersed bubbles. This interaction modifies the physical integrity of the gas-liquid membranes that maintain the small-bubble state within the digestive system.

Facilitating Gas Coalescence

The reduction in surface tension initiates a physical cascade by facilitating the collapse of the smaller, segregated gas bubbles. This allows the discrete gas elements to coalesce into fewer, larger gas pockets. This action alters the physical distribution of gas within the system.

Supporting Gas Elimination

The subsequent physiological consequence of this process is the more efficient expulsion of the aggregated gas. The larger gas pockets are more readily liberated and translocated through the GI tract, thereby supporting the body's natural mechanisms of gas elimination via eructation (belching) or flatus (passing gas).

Dosage and Administration Information

How Metsil (Metoclopramide) is Used

Metsil is administered through the oral, intravenous (IV), and intramuscular (IM) routes, with the choice of route determined by the clinical scenario, such as the need for rapid action or continuous maintenance. The forms include tablets, an oral solution, and a sterile injection solution.

Oral administration is typically timed so the dose is taken 30 minutes before each meal and at bedtime to align with the physiological need to enhance gastrointestinal motility. Injectable forms are typically administered as a slow injection over at least 1 to 2 minutes.

Labeled Dosing and Duration Constraints

The usage frequency and maximum duration vary based on the treated condition and geographic region:

  • Continuous Oral Use (US): The standard regimen for diabetic gastroparesis is 10 mg administered four times daily. The total treatment duration generally does not exceed 12 weeks.
  • Acute Use (EU/UK): The single dose is typically 10 mg, repeated up to three times daily, with a minimal interval of 6 hours between administrations. Treatment for these indications does not exceed 5 days.

Population-Specific Adjustments

Dose adjustments are utilized in specific patient groups. For individuals with moderate to severe renal or hepatic impairment, the usual dose is reduced by 50% to account for altered drug clearance. In pediatric patients in the EU/UK, dosing is calculated based on body weight (0.1 to 0.15 mg/kg) and is limited to three administrations per day.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides a comprehensive overview of the research exploring the compound and its components.


Research Scope

Research investigated the compound's activity. Variables measured in clinical studies have included assessments of joint mobility, pain perception, and joint stiffness.


Clinical Trial Summary

Double-blind, Placebo-controlled Study (N=150)

  • Objective: To evaluate the compound's influence on joint discomfort scores over 12 weeks.
  • Key Findings: Findings reported that participants receiving the compound had differences in their joint discomfort scores compared to the placebo group.
  • Biomarkers: Biomarkers studied included measures related to inflammation.

Combination Therapy Research

This combination was studied in a six-month trial (N=80) focused on the compound's ingredients together with a standard regimen. The study examined measurements related to cartilage status.

Comparative Research

A body of evidence has focused on the compound's activity across various patient populations, with a focus on its comparison against placebo. Further research continues to explore the compound's studied parameters.


Safety and Suitability Considerations in Research

Research outcomes included monitoring for adverse events. Monitoring captured a spectrum of occurrences, including those related to the gastrointestinal system.

Key Studies & References Metsil and Standard Regimen for Cartilage Status: A Six-Month Clinical Study in Osteoarthritic Patients

Frequently Asked Questions (FAQ)

Common questions about Metsil (FAQ)


Q: How quickly should I expect Metsil to start having an effect?

The time it takes for Metsil to begin working depends on how it is administered. Official product information states that intravenous injection is associated with onset of action within 1 to 3 minutes. Intramuscular administration is generally observed within 10 to 15 minutes, while the oral tablet or solution typically is observed within 30 and 60 minutes to achieve effect.


Q: What if I forget to take a dose of Metsil—is that a problem?

Official guidance related to a forgotten dose advises taking it as soon as it is remembered, unless it is near the time of the next dose. Regulatory instruction advises against taking a double dose to compensate for the missed one.


Q: How long does Metsil stay in your system after you stop taking it?

The official pharmacological data describes the time the drug remains in the body through its elimination half-life, which averages approximately 7 hours. This means the concentration of the drug is significantly reduced after this period. Based on this, the drug is considered to be substantially eliminated from the body within about one day after the last dose.


Q: Is Metsil known to be addictive or habit-forming?

Metsil is not classified as a controlled substance and is not generally considered to be addictive. However, official labeling does contain warnings regarding the potential for withdrawal symptoms if the medication is stopped abruptly after prolonged use. For this reason, official sources caution against sudden discontinuation without professional guidance.


Q: Does Metsil change the way birth control pills work?

According to available regulatory information, Metsil generally does not interfere with the effectiveness of hormonal birth control pills. However, official guidance notes that if the medication leads to severe vomiting or diarrhea that lasts longer than 24 hours, the protective effect of oral contraceptive pills may be reduced.


Q: Can I take Metsil if I also take a blood thinner?

Regulatory interaction databases do not report a major drug interaction between Metsil and certain common blood thinners. However, because unforeseen drug interactions are always a possibility, regulatory documents recommend professional monitoring for patients using both medications.


Q: Does Metsil require any special monitoring or regular blood tests?

While routine blood tests are not universally mandated for everyone taking the medicine, the official label notes that Metsil can cause hormonal changes, specifically hyperprolactinemia (elevated prolactin levels). Monitoring may be considered in certain patient populations who experience this specific side effect.


Q: Do generic versions of Metsil work the same as the brand name?

Official regulatory bodies mandate that a generic version of a medicine must be 'bioequivalent' to the brand-name product before it can be approved. This means the generic form is expected to work the same way in the body and provide the same overall benefits and risks as the original brand.


Q: Are there any known interactions between Metsil and common supplements like vitamins or herbal remedies?

Official drug documentation notes that patients should review all concurrent products with a healthcare provider, including over-the-counter medicines, vitamins, and herbal supplements. Interactions are possible with a wide range of substances, and this review helps to identify potential risks.


Q: What should I do if the side effects of Metsil don't go away?

Official patient information indicates that immediate medical attention is required if serious adverse reactions occur, such as signs of uncontrollable movements or symptoms of Neuroleptic Malignant Syndrome (NMS). Official guidance notes that consultation with a prescribing doctor is appropriate for side effects that are bothersome or persist.


Q: Is it normal to feel a change in appetite after starting Metsil?

The medication is sometimes prescribed to help address symptoms of delayed stomach emptying, which can include a loss of appetite. Therefore, a change in appetite can occur as the underlying condition is being managed. Any significant changes in appetite are noted as appropriate for discussion with a doctor.


Q: What happens if I miss several days of taking Metsil?

Official product information advises against abruptly stopping the medication, particularly after a long period of use, due to the risk of withdrawal symptoms. Since the drug has mandatory duration limits, any interruption or change in treatment regimen, particularly after missing several days, should be discussed with a doctor.


Q: Is there a known link between Metsil and feeling dizzy?

Yes, dizziness is officially included in the drug's safety profile as a possible adverse reaction. Official documentation notes the possible occurrence of dizziness.


Q: Can Metsil be crushed or split if someone has trouble swallowing pills?

To accommodate patients who have difficulty swallowing, Metsil is manufactured in various forms, including an oral solution and an orally disintegrating tablet (ODT). While these alternatives exist, the standard tablet form does not carry an official labeling or instruction for crushing or splitting.


Q: Can Metsil interact with treatments for high blood pressure?

Official documents indicate that Metsil can potentially affect blood pressure. The drug is advised against for patient populations with high blood pressure due to its potential to increase catecholamine levels. Regulatory guidelines indicate that discontinuation is required if a rapid increase in blood pressure is observed.


Q: How long does it take for Metsil's main benefit to become fully noticeable?

The time until the main clinical benefit is fully experienced can vary depending on the symptom being treated. For chronic conditions like diabetic gastroparesis, significant relief from nausea can occur early in treatment. However, official clinical trial summaries indicate that full relief from other symptoms, such as vomiting and feelings of abdominal fullness, may be observed after one week or more of consistent use.


Q: Does Metsil affect laboratory test results?

Official pharmacological information indicates that the medicine can influence certain physiological markers. Specifically, Metsil may cause an increase in the circulating levels of aldosterone and prolactin, which can affect the results of laboratory tests related to hormone and electrolyte balance.

How should Metsil be stored and disposed of?

Official Storage Requirements

Metsil (Simethicone) must be stored at room temperature, ensuring the area does not exceed 30 C (86 F), as stated in the product labeling. The medication must be kept in its original container and the lid must be tightly closed to protect the product from moisture and excessive heat. It is a mandatory handling requirement that the medicine must not be frozen to maintain its stability.

Child Safety and Disposal

All forms of Metsil must be stored out of the reach of children to prevent accidental ingestion. Unused or expired medicine should not be disposed of by flushing it down a toilet or sink. The officially recommended disposal method is utilizing a drug take-back program. If a take-back option is unavailable, the medicine can be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metsil found in:

A-Z Index: